Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

HIV Medicine

Volumn 16, Issue S1, 2015, Pages 46-54

  Soliman, Ez ^a   Sharma, S ^b   Arasteh K ^c   Wohl, D ^d   Achhra, A ^e   Tambussi, G ^f   O'Connor, J ^g   Stein, Jh ^h   Duprez, Da ⁱ   Neaton, Jd ^b   Phillips, A ^g  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Vivantes Auguste Viktoria Klinikum   (Germany)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

ⁱ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Cardiovascular risk; HIV; Strategic Timing of AntiRetroviral Treatment (START) trial

Indexed keywords

ADULT; AFRICA; ARTICLE; ASIA; AUSTRALIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; ELECTROCARDIOGRAM; EUROPE; FEMALE; FRAMINGHAM RISK SCORE; GEOGRAPHIC DISTRIBUTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; ISRAEL; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; OBESITY; PREVALENCE; PRIORITY JOURNAL; SMOKING; SOUTH AMERICA; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ELECTROCARDIOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

ADULT; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT;

EID: 84923345073     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12233     Document Type: Article

References (29)

1. Lewden C, Salmon D, Morlat P etal. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34: 121-130.
2. Lewden C, May T, Rosenthal E etal. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48: 590-598.
3. Crum NF, Riffenburgh RH, Wegner S etal. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41: 194-200.
4. Miller CJ, Baker JV, Bormann AM etal. Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy. PLoS One 2014; 9: e95061. doi: 10.1371/journal.pone.0095061.
5. Currier JS, Taylor A, Boyd F etal. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33: 506-512.
6. Friis-Møller N, Sabin CA, Weber R etal. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
7. Friis-Møller N, Reiss P, Sabin CA etal. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
8. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-2512.
9. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702-710.
10. Lang S, Mary-Krause M, Cotte L etal. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010; 24: 1228-1230.
11. Boccara F, Lang S, Meuleman C etal. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol 2013; 61: 511-523.
12. Achhra AC, Petoumenos K, Law MG. Relationship between CD4 cell count and serious long-term complications among HIV-positive individuals. Curr Opin HIV AIDS 2014; 9: 63-71.
13. Babiker AG, Emery S, Fätkenheuer G etal. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2013; 10 (Suppl 1): S5-S36.
14. Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings. Boston, MA, John Wright PSG Inc, 1982.
15. Soliman EZ, Prineas RJ, Roediger MP etal. Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. J Electrocardiol 2011; 44: 779-785.
16. Stamler J, Stamler R, Neaton JD etal. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy. JAMA 1999; 282: 2012-2018.
17. D'Agostino RB Sr, Vasan RS, Pencina MJ etal. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743-753.
18. Wilson PW, D'Agostino RB, Levy D etal. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
19. Friis-Møller N, Thiébaut R, Reiss P etal. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010; 17: 491-501.
20. Grinspoon SK, Grunfeld C, Kotler DP etal. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008; 118: 198-210.
21. Savès M, Chêne G, Ducimetière P etal. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37: 292-298.
22. Grinspoon S. Diabetes mellitus, cardiovascular risk, and HIV disease. Circulation 2009; 119: 770-772.
23. Grunfeld C, Kotler DP, Arnett DK etal. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation 2008; 118: e20-e28.
24. Greenland P, Knoll MD, Stamler J etal. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003; 290: 891-897.
25. Neuhaus J, Jacobs DR Jr, Baker JV etal. Markers of inflammation, coagulation and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201: 1788-1795.
26. Dube MP, Sattler FR. Inflammation and complications of HIV disease (editorial). J Infect Dis 2010; 201: 1783-1785.
27. Duprez DA, Neuhaus J, Kuller LH etal. Inflammation, coagulation and cardiovascular disease in HIV-infected patients. PLoS One 2012; 7: e44454. doi: 10.1371/journal.pone.0044454.
28. Nordell AD, McKenna M, Borges AH, Duprez D, Neuhaus J, Neaton JD, INSIGHT SMART, ESPRIT Study Groups, and SILCAAT Scientific Committee. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc 2014; 3: e000844. doi: 10.1161/JAHA.114.000844.
29. INSIGHT START Study Group. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. HIV Med 2015; 16 (Suppl 1): 1-9.